BOCA RATON, Fla., Feb. 7 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals (Nasdaq: NABI) announced today that Thomas H. McLain, chairman, chief executive officer and president, and Henrik Rasmussen, M.D., Ph.D., senior vice president, clinical, medical and regulatory affairs, will participate in the BIO CEO and Investor Conference 2007 on Monday, February 12, 2007, at the Waldorf Astoria Hotel, 301 Park Avenue, New York, New York. Mr. McLain will present a company overview at 11:00 am EST (Jade Room) and Dr. Rasmussen will participate in a panel discussion at 9:30 am EST (West Foyer) on Hepatitis C Virus (HCV): How Companies Are Ramping Up R&D.

Mr. McLain's presentation will be webcast live at: http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=NABI&item_id=1466799

The webcast will be available through March 12, 2007.

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. The company has two products on the market today: Nabi-HB® [Hepatitis B Immune Globulin (Human)], and Aloprim™ (allopurinol sodium) for Injection. Nabi Biopharmaceuticals is focused on developing products that address unmet medical needs and offer commercial opportunities in our core business areas: Hepatitis and transplant, Gram-positive bacterial infections and nicotine addiction. For a complete list of pipeline products, please go to: http://www.nabi.com/pipeline/index.php. The company is headquartered in Boca Raton, Florida. For additional information about Nabi Biopharmaceuticals, please visit our website at http://www.nabi.com.

SOURCE Nabi Biopharmaceuticals

CONTACT:
Thomas E. Rathjen
Vice President, Investor Relations
Nabi Biopharmaceuticals
+1-561-989-5800
Web site:http://www.nabi.com
(NABI)